TO THE EDITOR: Chimeric antigen receptor (CAR) T-cell therapy directed toward CD19 for B-cell malignancies often results in cytokine release syndrome (CRS).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile